Effects of atypical antipsychotic drug treatment on amphetamine induced striatal dopamine release in patients with psychotic disorders

Alan Breier, Tung Ping Su, Anil K. Malhotra, Igor Elman, Caleb M. Adler, Neil I. Weisenfeld, David Pickar

Research output: Contribution to journalArticle

14 Citations (Scopus)

Abstract

Clozapine, risperidone, and other new 'atypical' antipsychotic agents are distinguished from traditional neuroleptic drugs by having clinical efficacy with either no or low levels of extrapyramidal symptoms (EPS). Preclinical models have focused on striatal dopamine systems to account for their atypical profile. In this study, we examined the effects of clozapine and risperidone on amphetamine-induced striatal dopamine release in patients with psychotic disorders. A novel 11C-raclopride/PET paradigm was used to derive estimates of amphetamine-induced changes in striatal synaptic dopamine concentrations and patients were scanned while antipsychotic drug-free and during chronic treatment with either clozapine or risperidone. We found that amphetamine produced significant reductions in striatal 11C-raclopride binding during the drug-free and antipsychotic drug treatment phases of the study which reflects enhanced dopamine release in both conditions. There were no significant differences in % 11C-raclopride changes between the two conditions indicating that these atypical agents do not effect amphetamine-related striatal dopamine release. The implications for these data for antipsychotic drug action are discussed. Copyright (C) 1999 American College of Neuropsychopharmacology.

Original languageEnglish (US)
Pages (from-to)340-345
Number of pages6
JournalNeuropsychopharmacology
Volume20
Issue number4
DOIs
StatePublished - Apr 1999
Externally publishedYes

Fingerprint

Corpus Striatum
Amphetamine
Psychotic Disorders
Antipsychotic Agents
Dopamine
Raclopride
Risperidone
Clozapine
Therapeutics
Pharmaceutical Preparations

Keywords

  • Clozapine
  • Positron emission tomography
  • Raclopride
  • Risperidone
  • Schizophrenia

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of atypical antipsychotic drug treatment on amphetamine induced striatal dopamine release in patients with psychotic disorders. / Breier, Alan; Su, Tung Ping; Malhotra, Anil K.; Elman, Igor; Adler, Caleb M.; Weisenfeld, Neil I.; Pickar, David.

In: Neuropsychopharmacology, Vol. 20, No. 4, 04.1999, p. 340-345.

Research output: Contribution to journalArticle

Breier, Alan ; Su, Tung Ping ; Malhotra, Anil K. ; Elman, Igor ; Adler, Caleb M. ; Weisenfeld, Neil I. ; Pickar, David. / Effects of atypical antipsychotic drug treatment on amphetamine induced striatal dopamine release in patients with psychotic disorders. In: Neuropsychopharmacology. 1999 ; Vol. 20, No. 4. pp. 340-345.
@article{3a83fa0470214dc08f2dc06c3fafb70f,
title = "Effects of atypical antipsychotic drug treatment on amphetamine induced striatal dopamine release in patients with psychotic disorders",
abstract = "Clozapine, risperidone, and other new 'atypical' antipsychotic agents are distinguished from traditional neuroleptic drugs by having clinical efficacy with either no or low levels of extrapyramidal symptoms (EPS). Preclinical models have focused on striatal dopamine systems to account for their atypical profile. In this study, we examined the effects of clozapine and risperidone on amphetamine-induced striatal dopamine release in patients with psychotic disorders. A novel 11C-raclopride/PET paradigm was used to derive estimates of amphetamine-induced changes in striatal synaptic dopamine concentrations and patients were scanned while antipsychotic drug-free and during chronic treatment with either clozapine or risperidone. We found that amphetamine produced significant reductions in striatal 11C-raclopride binding during the drug-free and antipsychotic drug treatment phases of the study which reflects enhanced dopamine release in both conditions. There were no significant differences in {\%} 11C-raclopride changes between the two conditions indicating that these atypical agents do not effect amphetamine-related striatal dopamine release. The implications for these data for antipsychotic drug action are discussed. Copyright (C) 1999 American College of Neuropsychopharmacology.",
keywords = "Clozapine, Positron emission tomography, Raclopride, Risperidone, Schizophrenia",
author = "Alan Breier and Su, {Tung Ping} and Malhotra, {Anil K.} and Igor Elman and Adler, {Caleb M.} and Weisenfeld, {Neil I.} and David Pickar",
year = "1999",
month = "4",
doi = "10.1016/S0893-133X(98)00126-2",
language = "English (US)",
volume = "20",
pages = "340--345",
journal = "Neuropsychopharmacology",
issn = "0893-133X",
publisher = "Nature Publishing Group",
number = "4",

}

TY - JOUR

T1 - Effects of atypical antipsychotic drug treatment on amphetamine induced striatal dopamine release in patients with psychotic disorders

AU - Breier, Alan

AU - Su, Tung Ping

AU - Malhotra, Anil K.

AU - Elman, Igor

AU - Adler, Caleb M.

AU - Weisenfeld, Neil I.

AU - Pickar, David

PY - 1999/4

Y1 - 1999/4

N2 - Clozapine, risperidone, and other new 'atypical' antipsychotic agents are distinguished from traditional neuroleptic drugs by having clinical efficacy with either no or low levels of extrapyramidal symptoms (EPS). Preclinical models have focused on striatal dopamine systems to account for their atypical profile. In this study, we examined the effects of clozapine and risperidone on amphetamine-induced striatal dopamine release in patients with psychotic disorders. A novel 11C-raclopride/PET paradigm was used to derive estimates of amphetamine-induced changes in striatal synaptic dopamine concentrations and patients were scanned while antipsychotic drug-free and during chronic treatment with either clozapine or risperidone. We found that amphetamine produced significant reductions in striatal 11C-raclopride binding during the drug-free and antipsychotic drug treatment phases of the study which reflects enhanced dopamine release in both conditions. There were no significant differences in % 11C-raclopride changes between the two conditions indicating that these atypical agents do not effect amphetamine-related striatal dopamine release. The implications for these data for antipsychotic drug action are discussed. Copyright (C) 1999 American College of Neuropsychopharmacology.

AB - Clozapine, risperidone, and other new 'atypical' antipsychotic agents are distinguished from traditional neuroleptic drugs by having clinical efficacy with either no or low levels of extrapyramidal symptoms (EPS). Preclinical models have focused on striatal dopamine systems to account for their atypical profile. In this study, we examined the effects of clozapine and risperidone on amphetamine-induced striatal dopamine release in patients with psychotic disorders. A novel 11C-raclopride/PET paradigm was used to derive estimates of amphetamine-induced changes in striatal synaptic dopamine concentrations and patients were scanned while antipsychotic drug-free and during chronic treatment with either clozapine or risperidone. We found that amphetamine produced significant reductions in striatal 11C-raclopride binding during the drug-free and antipsychotic drug treatment phases of the study which reflects enhanced dopamine release in both conditions. There were no significant differences in % 11C-raclopride changes between the two conditions indicating that these atypical agents do not effect amphetamine-related striatal dopamine release. The implications for these data for antipsychotic drug action are discussed. Copyright (C) 1999 American College of Neuropsychopharmacology.

KW - Clozapine

KW - Positron emission tomography

KW - Raclopride

KW - Risperidone

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=0033028756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033028756&partnerID=8YFLogxK

U2 - 10.1016/S0893-133X(98)00126-2

DO - 10.1016/S0893-133X(98)00126-2

M3 - Article

C2 - 10088134

AN - SCOPUS:0033028756

VL - 20

SP - 340

EP - 345

JO - Neuropsychopharmacology

JF - Neuropsychopharmacology

SN - 0893-133X

IS - 4

ER -